Pneumococcal Vaccines Market
Market Insights on Pneumococcal Vaccines covering sales outlook, demand forecast & up-to-date key trends
Pneumococcal Vaccines Market by Product Type (Pneumococcal Polysaccharide Vaccines, Pneumococcal Conjugate Vaccines), Distribution Channel (Pharmacies, Community Clinics, Public Health Agencies) & Region - Forecast to 2021-2031
Pneumococcal Vaccines Market Snapshot
[187 pages] According to a survey conducted by ESOMAR-certified consulting firm Future Market Insights (FMI), the Pneumococcal Vaccines Market value is expected to total US$ 10.1 Bn in 2021. Driven by the rising prevalence of pneumococcal diseases across the globe, sales of pneumococcal vaccines are poised to increase by a CAGR of 7.3% over the forecast period 2021-2031.
Favored by the increasing number of government initiatives and growing awareness regarding the benefits of early vaccination, the pneumococcal vaccines market is likely to register an impressive year-on-year growth at 9.60% in 2021.
Let us know your requirement to get
100% FREE customization
Key Points Covered in Pneumococcal Vaccines Market Study
- Market estimates and forecast 2021-2031
- Key drivers and restraints impacting market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Brand share and Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact on Pneumococcal Vaccines Market and How to Navigate
- Recommendation on Key Winning Strategies
Pneumococcal Vaccines Market Historic Outlook Compared to the Forecast Period 2021-2031
The pneumococcal vaccines market grew at 8.90% CAGR between 2016 and 2020. The growth of the market can be attributed to the increasing prevalence of pneumococcal diseases such as bacteremic pneumonia, bloodstream infection, meningitis, bacteremia, and middle ear infection.
According to a study by the National Foundation for Infectious Diseases (NFID), nearly 1.3 million people in the U.S. visit emergency departments due to pneumonia, which causes death of around 50,000 people. The fatality rate is even higher in patient aged above 65 years.
The rising number of smokers, diabetes patients, heavy drinkers, and individuals living with chronic health conditions, who are vulnerable to infections and ailments due to their weakened immune system will create demand for pneumococcal vaccines.
Some of the leading manufacturers are taking initiatives to curb the incidence of pneumococcal diseases in Gavi-supported countries. For instance, in January 2018, Pfizer, one of the global pharmaceutical leaders, announced reducing the price of its PCV-13 4 dose vial vaccine from US$ 3.05 to US$ 2.95 per dose in Gavi-supported countries.
These developments are expected to create growth opportunities, enabling the market to expand at a CAGR of 9.60% through 2031.
What is the Impact of the Novel Coronavirus Outbreak on the Sales of Pneumococcal Vaccines?
The unprecedented outbreak of COVID-19 has substantially impacted the economies across the world. Various businesses and markets have been affected due to the regulatory lockdowns and imposed by the government, impeding the overall growth of industries.
However, the pandemic has positively impact the pneumococcal vaccines market, bolstering the sales over the past two years.
Some of the cases of novel coronavirus were placed in the same genre of diseases like pneumonia. Due to high similarities between coronavirus and pneumonia, medical professionals are increasingly using pneumococcal vaccines as a preventative measure against the high risk of lung infections caused by the disease.
According to a report published by World Health Organization (WHO) on 4th August 2021, approximately 199,466,211 cases has been confirmed across the globe with over 4,244,541 fatalities.
This rising cases of COVID-19 coupled with emerging new strains of coronavirus such asOC43, HKU1, and SARS-CoV among other is creating remunerative opportunities for the market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow are Government Initiatives Driving Pneumococcal Vaccines Market?
Governments across various countries are adopting various initiatives to reduce the burden of pneumococcal diseases. For instance, in India, the Ministry of Health and Family Welfare (MoHFW) has undertaken initiative named, Social Action and Awareness to Neutralise Pneumonia Successfully (SAANS). The goal of SAANA is to spread the awareness regarding the routine pneumococcal immunization programs to curb the incidence of pneumonia.
Similarly, international organizations are contributing towards the goal. For instance, the WHO and United Nations Children’s Emergency Fund (UNICEF) have also introduced an initiative named, the Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). The aim of GAPPD is to protect, prevent, and treat children from pneumonia and diarrhea.
Due to the efforts of these organization, several countries across the globe are progressively introducing pneumococcal conjugate vaccine (PCV) for infants and children aged from 6 weeks to 5 years for routine immunization and to prevent pneumococcal diseases and acute otitis media. As per a report by the World Health Organization (WHO), pneumococcal vaccine have been introduce in over 134 countries by the end of 2016 and covering about 42% of the world.
Thus, government initiatives are expected to help the pneumococcal vaccines market to expand over the coming year.
Pneumococcal Vaccines Market - Country-wise Insights
Why is Demand for Pneumococcal Vaccines Rising in the U.S.?
As per the FMI, the U.S. is anticipated to dominate the market in North America. The market for pneumococcal vaccines in the U.S. is bolstering due to high prevalence of pneumococcal disorders such as bacteremic pneumonia, bloodstream infection, and meningitis.
As per a report by the Centers of Disease Control and Prevention, more than 150,000 people in in the U.S. are hospitalized because of the pneumococcal pneumonia and around 3,500 people die due to pneumococcal meningitis and bacteremia. Thus, with the rise in prevalence of these diseases, the market in the U.S. is expected to expand at a rapid pace.
How is the Market for Pneumococcal Vaccines Flourishing in the U.K.?
In Europe, the U.K. is emerging as the most lucrative market on the back on presence of some of the leading pharmaceutical companies such as GlaxoSmithKline (GSK), AstraZeneca, Pfizer UK, and Shire.
Growing number of clinical trials and research and development activities for development of effective pneumococcal vaccines is estimated to provide enormous opportunities for the growth of the market. This will also fulfil the demand for vaccines for multiple serotypes in the country.
Owing to the presence of well-developed medical infrastructure and high consumer spending on the healthcare, the market in the U.K. is likely to project a steady growth over the coming years.
Why is the Demand for Pneumococcal Vaccines Spurring in India?
Issues concerning rising prevalence of pneumococcal diseases among children under the age of five have is increasing with urbanization in the country. As per a report published by Johns Hopkins Bloomberg School of Public Health named, Pneumonia & Diarrhea report 2020, India account for the largest number of deaths of children bellow 5 year out of 15 countries.
Thus to curb the burden of these diseases, government of the country is increasing undertaking initiatives to spread the awareness regarding the pneumococcal diseases.
For instance, Global Coalition against Child Pneumonia (GCCP) committee form by the government to promote interventions for protecting, preventing, and treating pneumonia is celebrating World Pneumonia Day in 12th November. This is to spread awareness regarding pneumonia and highlight the seriousness of disease as a public health problem across the country. Such initiatives are expected to propelling the demand for pneumococcal vaccines in India.
What are the Growth Prospects for Pneumococcal Vaccines Market in China?
A steady rise in investment across the medical healthcare has be witnessed in China, especially, due to the outbreak of coronavirus in the country. According to a report by WHO, around 121,067 cases of coronavirus has been reported in China with a 5,639 death over the last year.
Owing to the increasing use of pneumococcal vaccines by the medical institutes in the treatment of COVID-19, China is estimated to emerge as one of the most remunerative market in landscape.
Increasing number of medical institutes and hospitals in the country is also expected to bolster the sales of pneumococcal vaccines in the country.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Pneumococcal Vaccines Market- Category-wise Insights
Why is Demand for Pneumococcal Conjugate Vaccines High?
Pneumococcal conjugate vaccines are estimated to lead the product type, registering high growth in the global pneumococcal vaccines market.
Increasing adoption of pneumococcal conjugate vaccines for routine immunization of kids below 5 years to prevent them from fatal pneumococcal diseases and acute otitis media across the developing economies is projected to spur the sales.
In response to increasing number of research and development activities for developing new conjugate vaccines for expanding indications, the segment is likely to witness vigorous growth at through 2031.
Why do the Public Health Agencies Account for Maximum Share in Pneumococcal Vaccines Sales?
Among pharmacies, public health agencies, and community clinics, public health agencies are anticipated to account for the largest market share driven by the large amount of vaccine purchases by the organization such as WHO, GAVI, UNICEF, and other.
These organization purchase massive amount of pneumonia vaccines from the manufacturers to distribute them directly to the destination geographies for the social cause. Thus, on account of increasing number of initiatives undertaken by these organization, the segment is expected to emerge as the center point for the expansion of the market.
Pneumococcal Vaccines Market - Competitive Landscape
Leading players operating in the pneumococcal vaccines market are focusing on research and development for new product development to enhance their product portfolio and engaging into strategic collaboration, agreement, merger & acquisition with other market players to gain competitive edge over other players. For instance,
- Merck & Co., Inc., is focusing on developing new Merck’s V114, 15-valent pneumococcal conjugate vaccine. In September 2020, the company announced results for V114 from phase 2 & phase 3 studies and its respond on all 15 serotypes of pneumonia.
- In September 2020, Shinogi, a Japanese pharmaceutical company announced entering into a license agreement with a next-generation nasal vaccines manufacturer. HanaVax. The agreement with assist the company in R&D, manufacturing, commercialization, and distribution of Streptococcus pneumoniae developed by HanaVax.
Pneumococcal Vaccines Market - Scope of Report
|
Attribute |
Details |
|
Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
|
Pneumococcal Vaccines Market Analysis |
USD Million for Value |
|
Key Regions Covered |
North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa
|
|
Key Countries Covered |
US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa |
|
Pneumococcal Vaccines Market - Key Segments Covered |
Product Type, Distribution Channel, and Regions |
|
Pneumococcal Vaccines Market - Key Companies Profiled |
|
|
Pneumococcal Vaccines Market - Report Coverage |
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
|
Customization & Pricing |
Available upon Request |
Pneumococcal Vaccines Market by Category
By Product Type:
- Pneumococcal Polysaccharide Vaccines
- Pneumococcal Conjugate Vaccines
By Distribution Channel:
- Pharmacies
- Community Clinics
- Public Health Agencies
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific Excluding Japan
- Japan
- Oceania
- MEA
Frequently Asked Questions
The pneumococcal vaccines market is expected to surpass a valuation of US$ 10124.9 in 2021.
The pneumococcal vaccines market witnessed impressive growth at 8.90% CAGR between 2016 and 2020.
Expansion of product indication and increasing Pharmacy-based Immunization Services (PBIS) will spur the sales.
GlaxoSmithKline Plc., Pfizer Inc., Merck & Co., Inc., and Sanofi SA. are the top players leading the pneumococcal vaccines market.
Demand for infant formula will continue to rise backed by rising prevalence of pneumococcal diseases in the country, sales across North America are set to surge at a robust CAGR of 8.25% through 2031.
The market for pneumococcal vaccines in Europe will exhibit a steady growth at 7.39% CAGR during the forecast period 2021-2031.
Top countries in terms of pneumococcal vaccines sales are the U.S., France, Germany, Canada, and the U.K.
Leading players of global pneumococcal vaccines market is expected to contribute around 85-90% of total market share.
In 2021 key countries that are Japan and South Korea are estimated to account for 5% and less than 1% market share respectively in global pneumococcal vaccines market.
Table of Content
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Pneumococcal Vaccines Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Key Trends
5. Key Inclusions
5.1. Disease Epidemiology
5.2. Reimbursement Scenario
5.3. Pipeline Assessment
6. Respiratory Syncytial Virus (RSV) Vaccines Market, Pipeline Assessment
7. North America Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis By Country, 2016–2020
7.2.1. U.S.
7.2.2. Canada
7.3. Market Size (US$ Mn) Forecast By Country, 2021–2031
7.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020
7.4.1. Pneumococcal Conjugate Vaccines
7.4.2. Pneumococcal Polysaccharide Vaccines
7.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031
7.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020
7.6.1. Pharmacies
7.6.2. Community Clinics
7.6.3. Public Health Agencies
7.6.4. Others
7.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031
7.8. Market Attractiveness Analysis
7.8.1. By Country
7.8.2. By Product
7.8.3. By Distribution Channel
7.9. Key Market Participants – Intensity Mapping
8. Latin America Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031
8.1. Introduction
8.2. Historical Market Size (US$ Mn) By Country, 2016–2020
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Market Size (US$ Mn) Forecast By Country, 2021–2031
8.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020
8.4.1. Pneumococcal Conjugate Vaccines
8.4.2. Pneumococcal Polysaccharide Vaccines
8.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031
8.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020
8.6.1. Pharmacies
8.6.2. Community Clinics
8.6.3. Public Health Agencies
8.6.4. Others
8.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031
8.8. Market Attractiveness Analysis
8.8.1. By Country
8.8.2. By Product
8.8.3. By Distribution Channel
8.9. Key Market Participants – Intensity Mapping
9. Western Europe Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031
9.1. Introduction
9.2. Historical Market Size (US$ Mn) By Country, 2016–2020
9.2.1. Germany
9.2.2. France
9.2.3. U.K.
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Western Europe
9.3. Market Size (US$ Mn) Forecast By Country, 2021–2031
9.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020
9.4.1. Pneumococcal Conjugate Vaccines
9.4.2. Pneumococcal Polysaccharide Vaccines
9.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031
9.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020
9.6.1. Pharmacies
9.6.2. Community Clinics
9.6.3. Public Health Agencies
9.6.4. Others
9.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031
9.8. Market Attractiveness Analysis
9.8.1. By Country
9.8.2. By Product
9.8.3. By Distribution Channel
9.9. Key Market Participants – Intensity Mapping
10. Eastern Europe Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031
10.1. Introduction
10.2. Historical Market Size (US$ Mn) By Country, 2016–2020
10.2.1. Russia
10.2.2. Poland
10.2.3. Rest of Eastern Europe
10.3. Market Size (US$ Mn) Forecast By Country, 2021–2031
10.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020
10.4.1. Pneumococcal Conjugate Vaccines
10.4.2. Pneumococcal Polysaccharide Vaccines
10.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031
10.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020
10.6.1. Pharmacies
10.6.2. Community Clinics
10.6.3. Public Health Agencies
10.6.4. Others
10.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031
10.8. Market Attractiveness Analysis
10.8.1. By Country
10.8.2. By Product
10.8.3. By Distribution Channel
10.9. Key Market Participants – Intensity Mapping
11. Asia Pacific excluding Japan and China (APEJ) Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031
11.1. Introduction
11.2. Historical Market Size (US$ Mn) By Country, 2016–2020
11.2.1. India
11.2.2. China
11.2.3. Australia and New Zealand
11.2.4. ASEAN
11.2.5. Rest of APEJ
11.3. Market Size (US$ Mn) Forecast By Country, 2021–2031
11.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020
11.4.1. Pneumococcal Conjugate Vaccines
11.4.2. Pneumococcal Polysaccharide Vaccines
11.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031
11.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020
11.6.1. Pharmacies
11.6.2. Community Clinics
11.6.3. Public Health Agencies
11.6.4. Others
11.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031
11.8. Market Attractiveness Analysis
11.8.1. By Country
11.8.2. By Product
11.8.3. By Distribution Channel
11.9. Key Market Participants – Intensity Mapping
12. Japan Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020
12.2.1. Pneumococcal Conjugate Vaccines
12.2.2. Pneumococcal Polysaccharide Vaccines
12.3. Market Size (US$ Mn) Forecast By Product Type, 2021–2031
12.4. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020
12.4.1. Pharmacies
12.4.2. Community Clinics
12.4.3. Public Health Agencies
12.4.4. Others
12.5. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Distribution Channel
12.7. Key Market Participants – Intensity Mapping
13. MEA Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031
13.1. Introduction
13.2. Market Size (US$ Mn) Forecast By Country, 2021–2031
13.3. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020
13.3.1. Pneumococcal Conjugate Vaccines
13.3.2. Pneumococcal Polysaccharide Vaccines
13.4. Market Size (US$ Mn) Forecast By Product Type, 2021–2031
13.5. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020
13.5.1. Pharmacies
13.5.2. Community Clinics
13.5.3. Public Health Agencies
13.5.4. Others
13.6. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031
13.7. Market Attractiveness Analysis
13.7.1. By Country
13.7.2. By Product
13.7.3. By Distribution Channel
13.8. Key Market Participants – Intensity Mapping
14. Forecast Factors: Relevance and Impact
15. Drivers and Restraints: Impact Analysis
16. Macroeconomic Assumptions
17. Market Share Analysis
18. Competition Analysis
18.1. Competition Dashboard
18.2. Company Deep Dive
18.2.1. Pfizer Inc.
18.2.1.1. Overview
18.2.1.2. Product Portfolio
18.2.1.3. Production Footprint
18.2.1.4. Sales Footprint
18.2.1.5. Strategy
18.2.1.5.1. Marketing Strategy
18.2.1.5.2. Product Strategy
18.2.1.5.3. Channel Strategy
18.2.2. Merck & Co., Inc.
18.2.2.1. Overview
18.2.2.2. Product Portfolio
18.2.2.3. Production Footprint
18.2.2.4. Sales Footprint
18.2.2.5. Strategy
18.2.2.5.1. Marketing Strategy
18.2.2.5.2. Product Strategy
18.2.2.5.3. Channel Strategy
18.2.3. GlaxoSmithKline plc.
18.2.3.1. Overview
18.2.3.2. Product Portfolio
18.2.3.3. Production Footprint
18.2.3.4. Sales Footprint
18.2.3.5. Strategy
18.2.3.5.1. Marketing Strategy
18.2.3.5.2. Product Strategy
18.2.3.5.3. Channel Strategy
18.2.4. Sanofi SA
18.2.4.1. Overview
18.2.4.2. Product Portfolio
18.2.4.3. Production Footprint
18.2.4.4. Sales Footprint
18.2.4.5. Strategy
18.2.4.5.1. Marketing Strategy
18.2.4.5.2. Product Strategy
18.2.4.5.3. Channel Strategy
19. Global Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031, By Region
19.1. Introduction / Key Findings
19.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2016–2020
19.2.1. North America
19.2.2. Western Europe
19.2.3. Eastern Europe
19.2.4. Latin America
19.2.5. Asia Pacific excluding Japan
19.2.6. Japan
19.2.7. Middle East and Africa
19.3. Market Size (US$ Mn) Forecast By Region, 2021–2031
19.4. Market Attractiveness Analysis By Region
20. Global Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031, By Product
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020
20.2.1. Pneumococcal Conjugate Vaccines
20.2.2. Pneumococcal Polysaccharide Vaccines
20.3. Market Size (US$ Mn) Forecast By Product Type, 2021–2031
20.4. Market Attractiveness Analysis By Product Type
21. Global Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031, By Distribution Channel
21.1. Introduction
21.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020
21.2.1. Pharmacies
21.2.2. Community Clinics
21.2.3. Public Health Agencies
21.2.4. Others
21.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031
21.4. Market Attractiveness Analysis By Distribution Channel
22. Global Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031
22.1. Market Value Share Analysis
22.1.1. By Country
22.1.2. By Product
22.1.3. By Distribution Channel
22.2. Y-o-Y Growth Analysis
22.2.1. By Country
22.2.2. By Product
22.2.3. By Distribution Channel
22.3. Absolute $ Opportunity
23. Assumptions and Acronyms
24. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1a: Factors Considered While Setting Vaccine Prices, By Company
Table 1b: Factors Considered While Setting Vaccine Prices, By Company
Table 02a: Pneumococcal Vaccines Market Pipeline Analysis (2021)
Table 02b: Pneumococcal Vaccines Market Pipeline Analysis (2021)
Table 02c: Pneumococcal Vaccines Market Pipeline Analysis (2021)
Table 02d: Pneumococcal Vaccines Market Pipeline Analysis (2021)
Table 03a: RSV Vaccines Market Pipeline Analysis (2021)
Table 03b: RSV Vaccines Market Pipeline Analysis (2021)
Table 03c: RSV Vaccines Market Pipeline Analysis (2021)
Table 03d: RSV Vaccines Market Pipeline Analysis (2021)
Table 03e: RSV Vaccines Market Pipeline Analysis (2021)
Table 03f: RSV Vaccines Market Pipeline Analysis (2021)
Table 04: North America Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country
Table 05: North America Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type
Table 06: North America Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel
Table 07: Latin America Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country
Table 08: Latin America Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type
Table 09: Latin America Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel
Table 10: Western Europe Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country
Table 11: Western Europe Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type
Table 12: Western Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel
Table 13: Eastern Europe Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country
Table 14: Eastern Europe Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type
Table 15: Eastern Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel
Table 16: APEJ Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country
Table 17: APEJ Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type
Table 18: APEJ Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel
Table 19: Japan Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type
Table 20: Japan Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel
Table 21: MEA Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country
Table 22: MEA Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type
Table 23: MEA Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel
Table 24: Global Pneumococcal Vaccines Market Size (US$ Mn) Forecast By Region, 2021–2031
Table 25: Global Pneumococcal Vaccines Market size Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type
Table 26: Global Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Market Size (US$ Mn) by Region (2021A & 2031F)
Figure 02: Global Pneumococcal Vaccines Market Value Share By Product Type 2021 (A)
Figure 03: Global Pneumococcal Vaccines Market Value Share By Product Type 2021 (A)
Figure 04: Tiered-price Policies Among Vaccine Manufacturers
Figure 05: Pneumococcal Vaccine Procured Volumes 2021-2031 (in millions of doses)
Figure 06: Countries Approved for Gavi's Pneumococcal Vaccine Support-
Figure 07: Trends in Invasive Pneumococcal Diseases Among Children Aged <5 year Old, 2021–2031
Figure 08: Summary of AMC Financial Process Flow And Funds Disbursed in Private-public Partnerships (Inception to 31 December 2021)
Figure 09: Countries With Pneumococcal Conjugate Vaccine in The National Immunization Program and Planned Introductions (In 2018)
Figure 10: Global Coverage of Older Vaccines vs. Newer Vaccines (2016)
Figure 11: Comparison of PCV Uptake in High-income, Gavi-eligible and Gavi-ineligible Countries, 2016–2020
Figure 12: Number of Children Who Were Unvaccinated, By Country
Figure 13: Distribution of Industry Sponsored Clinical Programs for Pneumococcal Vaccines, by Phase
Figure 14: Distribution of Industry Sponsored Clinical Programs for Pneumococcal Vaccines, by Age Group
Figure 15: Geographical Distribution of Clinical Trials for Pneumococcal Vaccines (2021)
Figure 16: Distribution of Industry Sponsored Clinical Programs for RSV Vaccines, by Phase
Figure 17: Distribution of Industry Sponsored Clinical Programs for RSV Vaccines, by Age Group
Figure 18: Geographical Distribution of Clinical Trials for RSV Vaccines (2021)
Figure 19: North America Pneumococcal Vaccines Market Split By Product Type (2018)
Figure 20: North America Pneumococcal Vaccines Market Split By Distribution Channel (2018)
Figure 21: North America Pneumococcal Vaccines Market Split By Country (2018)
Figure 22: North America Pneumococcal Vaccines Market Size Analysis, 2021–2031
Figure 23: North America Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031
Figure 24: U.S. Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 25: U.S. Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 26: Canada Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 27: Canada Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 28: North America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines
Figure 29: North America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines
Figure 30: North America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines
Figure 31: North America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines
Figure 32: North America Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031
Figure 33: North America Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031
Figure 34: North America Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031
Figure 35: Latin America Pneumococcal Vaccines Market Split By Product Type (2018)
Figure 36: Latin America Pneumococcal Vaccines Market Split By Distribution Channel (2018)
Figure 37: Latin America Pneumococcal Vaccines Market Split By Country (2018)
Figure 38: Latin America Pneumococcal Vaccines Market Size Analysis, 2021–2031
Figure 39: Latin America Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031
Figure 40: Brazil Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 41: Brazil Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 42: Mexico Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 43: Mexico Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 44: Rest of Latin America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 45: Rest of Latin America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 46: Latin America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines
Figure 47: Latin America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines
Figure 48: Latin America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines
Figure 49: Latin America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines
Figure 50: Latin America Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031
Figure 51: Latin America Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031
Figure 52: Latin America Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031
Figure 53: Western Europe Pneumococcal Vaccines Market Split By Product Type (2018)
Figure 54: Western Europe Pneumococcal Vaccines Market Split By Distribution Channel (2018)
Figure 55: Western Europe Pneumococcal Vaccines Market Split By Country (2018)
Figure 56: Western Europe Pneumococcal Vaccines Market Size Analysis, 2021–2031
Figure 57: Western Europe Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031
Figure 58: U.K. Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 59: U.K. Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 60: France Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 61: France Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 62: Germany Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 63: Germany Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 64: Italy Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 65: Italy Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 66: Spain Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 67: Spain Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 68: Rest of Western Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 69: Rest of Western Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 70: Western Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines
Figure 71: Western Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines
Figure 72: Western Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines
Figure 73: Western Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines
Figure 74: Western Europe Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031
Figure 75: Western Europe Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031
Figure 76: Western Europe Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031
Figure 77: Eastern Europe Pneumococcal Vaccines Market Split By Product Type (2018)
Figure 78: Eastern Europe Pneumococcal Vaccines Market Split By Distribution Channel (2018)
Figure 79: Eastern Europe Pneumococcal Vaccines Market Split By Country (2018)
Figure 80: Eastern Europe Pneumococcal Vaccines Market Size Analysis, 2021–2031
Figure 81: Eastern Europe Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031
Figure 82: Russia Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 83: Russia Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 84: Poland Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 85: Poland Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 86: Rest of Eastern Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 87: Rest of Eastern Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 88: Eastern Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines
Figure 89: Eastern Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines
Figure 90: Eastern Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines
Figure 91: Eastern Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines
Figure 92: Eastern Europe Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031
Figure 93: Eastern Europe Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031
Figure 94: Eastern Europe Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031
Figure 95: APEJ Pneumococcal Vaccines Market Split By Product Type (2018)
Figure 96: APEJ Pneumococcal Vaccines Market Split By Distribution Channel (2018)
Figure 97: APEJ Pneumococcal Vaccines Market Split By Country (2018)
Figure 98: APEJ Pneumococcal Vaccines Market Size Analysis, 2021–2031
Figure 99: APEJ Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031
Figure 100: India Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 101: India Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 102: Australia & New Zealand Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 103: Australia & New Zealand Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 104: China Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 105: China Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 106: ASEAN Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 107: ASEAN Australia & New Zealand Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 108: Rest of APEJ Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 109: Rest of APEJ Australia & New Zealand Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 110: APEJ Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines
Figure 111: APEJ Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines
Figure 112: APEJ Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines
Figure 113: APEJ Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines
Figure 114: APEJ Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031
Figure 115: APEJ Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031
Figure 116: APEJ Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031
Figure 117: Japan Pneumococcal Vaccines Market Split By Product Type (2018)
Figure 118: Japan Pneumococcal Vaccines Market Split By Distribution Channel (2018)
Figure 119: Japan Pneumococcal Vaccines Market Size Analysis, 2021–2031
Figure 120: Japan Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031
Figure 121: Japan Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines
Figure 122: Japan Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines
Figure 123: Japan Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines
Figure 124: Japan Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines
Figure 125: Japan Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031
Figure 126: Japan Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031
Figure 127: MEA Pneumococcal Vaccines Market Split By Product Type (2018)
Figure 128: MEA Pneumococcal Vaccines Market Split By Distribution Channel (2018)
Figure 129: MEA Pneumococcal Vaccines Market Split By Country (2018)
Figure 130: MEA Pneumococcal Vaccines Market Size Analysis, 2021–2031
Figure 131: MEA Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031
Figure 132: South Africa Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 133: South Africa Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 134: GCC Countries Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 135: GCC Countries Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 136: Rest of MEA Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031
Figure 137: Rest of MEA Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031
Figure 138: MEA Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines
Figure 139: MEA Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines
Figure 140: MEA Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines
Figure 141: MEA Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines
Figure 142: MEA Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031
Figure 143: MEA Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031
Figure 144: MEA Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031
Figure 145 : Global Pneumococcal Vaccines Market Share Analysis (%) By Region, 2021 & 2031
Figure 146: Global Pneumococcal Vaccines Market Y-o-Y Growth (%) By Region, 2021–2031
Figure 147: Global Pneumococcal Vaccines Market Attractiveness Analysis By Region, 2021–2031
Figure 148: Global Pneumococcal Vaccines Market Share Analysis (%) By Product Type, 2021 & 2031
Figure 149: Global Pneumococcal Vaccines Market Y-o-Y Growth (%) By Product Type, 2021–2031
Figure 150: Global Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031
Figure 151: Global Pneumococcal Vaccines Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 152: Global Pneumococcal Vaccines Market Y-o-Y Growth (%) By Distribution Channel, 2021–2031
Figure 153: Global Pneumococcal Vaccines Market Attractiveness Analysis By distribution channel , 2021–2031
Figure 154: Global Pneumococcal Vaccines Market Value Analysis and Forecast, 2021–2028 (US$ Mn)
Figure 155: Global Pneumococcal Vaccines Market Absolute $ Opportunity (US$ Mn), 2021–2031
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
